Cargando…
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
BACKGROUND: Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different effect on cardiovascular (CV) outcomes. The present study is to evalua...
Autores principales: | Zhang, Zeqing, Chen, Xi, Lu, Puhan, Zhang, Jianhua, Xu, Yongping, He, Wentao, Li, Mengni, Zhang, Shujun, Jia, Jing, Shao, Shiying, Xie, Junhui, Yang, Yan, Yu, Xuefeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333444/ https://www.ncbi.nlm.nih.gov/pubmed/28249585 http://dx.doi.org/10.1186/s12933-017-0512-z |
Ejemplares similares
-
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020) -
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022) -
The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012) -
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022) -
Insulin upregulates betatrophin expression via PI3K/Akt pathway
por: Lu, Puhan, et al.
Publicado: (2017)